Navigation Links
Oxford Resource Partners, LP and Mendel Biotechnology, Inc. Announce a Miscanthus Biomass Pilot Project in Ohio
Date:9/21/2010

al in Northern Appalachia and the Illinois Basin.  Oxford markets its coal primarily to large electric utilities with coal-fired, base-load scrubbed power plants under long-term coal sales contracts.  As of December 31, 2009, Oxford controlled 91.6 million tons of proven and probable coal reserves, and it currently operates 17 active mines that are managed as eight mining complexes.  Oxford is headquartered in Columbus, Ohio.

For more information about Oxford Resource Partners, LP (NYSE: OXF), please visit www.oxfordresources.com.  Financial and other information about Oxford is routinely posted on and accessible at www.oxfordresources.com.

About Mendel Biotechnology, Inc.

Mendel Biotechnology, Inc. is a pioneer in the application of functional genomics to the study of plant genes and is a leading developer of dedicated energy crops for the bioenergy markets. Mendel has relationships with leading agricultural, energy, forestry and horticulture companies for the commercialization of improved seed and plant products, and is developing new seed and feedstock products for the emerging bioenergy market. For more information about Mendel Biotechnology, Inc., please visit www.mendelbio.com.

FORWARD-LOOKING STATEMENTS: Except for historical information, statements made in this press release are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934, as amended.  All statements, other than statements of historical facts, included in this press release that address activities, events or developments that the Company expects, believes or anticipates will or may occur in the future are forward-looking statements. These state
'/>"/>

SOURCE Oxford Resource Partners, LP
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Oxford Finance Corporation Hires Dr. Killu Sanborn to Support Life Science Business Development in Western North America
2. ALS Therapy Development Institute and Oxford BioMedica Begin Second Phase of Collaboration to Develop Gene Therapies for Amyotrophic Lateral Sclerosis
3. Oxford BioTherapeutics Appoints Michael Moore as Chairman
4. Oxford Performance Materials Introduces OXPEKK PermettaTM High Performance Polymer Films
5. TED Conferences Announces 25 TED Fellows for TEDGlobal in Oxford
6. The Court Supports Bavarian Nordics Decision to Start Patent Infringement Case Against Oxford BioMedica
7. Bavarian Nordics Case Against Oxford BioMedica
8. New Dual Wavelength X-ray Diffractometer From Oxford Diffraction, Now a Part of Varian, Inc., Allows Increased Throughput for Challenging Single Crystal Analyses
9. New resource examines questions about the role of nanoscience
10. Web Resource for Interferon Research
11. Gramene Announces Scholarships for Groups Underrepresented in Science to Learn How to Use Bioinformatics and Genomics Resources
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/16/2015)... (PRWEB) April 16, 2015 ... at Charlotte (UNC Charlotte) spin-out company, announced today ... Cooper, Ph.D., M.D., as Chief Operating Officer (COO). ... of experience in developing clinical diagnostic and biotechnology ... infectious disease. , Cooper’s extensive career transcends the ...
(Date:4/16/2015)... Md. , April 16, 2015  RegeneRx ... today announced its U.S. joint venture with G-treeBNT ... a phase 3 clinical trial for the orphan ... confirmatory trial for dry eye syndrome (DES) in ... preservative-free eye drops, RGN-259/GBT201, this year.  Each of ...
(Date:4/16/2015)... 16, 2015  AnaptysBio, Inc., a leader in ... today announced the advancement of its first-in-class ... studies. The Company,s anti-IL-36R therapeutic antibody, called ... pustular psoriasis (GPP), an orphan systemic inflammatory ... wholly owned within AnaptysBio,s proprietary antibody pipeline ...
(Date:4/16/2015)... LAUSANNE , Switzerland ... Debiopharm International SA (Debiopharm), part of Debiopharm Group ™ ... prescription drugs that target unmet medical needs ... that preclinical data on the investigational compounds ... inhibitor) will be presented at the 2015 ...
Breaking Biology Technology:OncoTAb Names Dr. David L. Cooper as COO 2RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 2RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 3RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 4RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 5AnaptysBio Advances First-In-Class Anti-IL-36 Receptor Antibody Program To Treat Orphan Inflammatory Disease 2Debiopharm International SA Announces Results of 2 Key Oncology Programs at 2015 AACR Conference 2Debiopharm International SA Announces Results of 2 Key Oncology Programs at 2015 AACR Conference 3
... Vaccinex, Inc. announced today,that Dr. John E. ... will,be actively involved in the strategic planning and ... Dr. Leonard has over 20 years of experience ... level positions in Regulatory Affairs, Quality,Project Management and ...
... March 5 AcroMetrix, a global leader ... and serological,diagnostics, announced today that it has ... for the development and supply of molecular ... AcroMetrix provides In Vitro Diagnostic manufacturers and ...
... the German,Bundestag (Lower House) is due to vote on ... poles in the debate on embryonic stem cell research,could ... the complete,liberalisation of stem cell research, while its critics ... of human stem cells, which are produced from,embryos. While ...
Cached Biology Technology:John E. Leonard, Ph.D., Former Biogen Idec Antibody Development Executive, Joins the Scientific Advisory Board of Vaccinex, Inc. 2AcroMetrix Signs Development and Supply Agreement With Beckman Coulter Inc. for Molecular Quality Control Standards 2A New Era in Cell Biology: German Company Develops Groundbreaking Alternative to Stem Cell Therapy 2A New Era in Cell Biology: German Company Develops Groundbreaking Alternative to Stem Cell Therapy 3
(Date:3/20/2015)... --Research and Markets ( http://www.researchandmarkets.com/research/4stcg3/india_sensors ) ... Sensors Market Forecast and Opportunities 2020" report ... is projected to grow at a CAGR over ... industrial and healthcare sectors are the key application ... adoption of MEMS technology in sensors is growing ...
(Date:3/20/2015)... and Markets ( http://www.researchandmarkets.com/research/vkzvcs/iris_biometrics ) has announced the ... Report" report to their offering. This report ... The report provides separate comprehensive analytics for the US, ... Europe , Asia-Pacific , ... . Annual estimates and forecasts are provided ...
(Date:3/17/2015)... 2015 MedNet Solutions , a ... study management systems, is pleased to announce that ... Outsourcing in Clinical Trials Southeast conference – March ... excellent forum for MedNet to showcase iMedNet ... (SaaS) eClinical technology platform. We strongly ...
Breaking Biology News(10 mins):India Sensors Market Forecast and Opportunities 2020 - STMicroelectronics held the largest share in 2014 2India Sensors Market Forecast and Opportunities 2020 - STMicroelectronics held the largest share in 2014 3Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 2Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 3Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 4Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 5Connect With MedNet Solutions At Outsourcing In Clinical Trials Southeast 2
... discovered how to block a molecular switch that triggers brain ... The Hopkins study, conducted on mice, is believed to be ... of nerve cells called the EP1 receptor is the switch, ... off. , The finding holds promise for the ...
... crops have something in common. That knowledge, gleaned ... could open the gate to advances in both ... appeared online this month in advance of regular ... of basic-science firsts that offer immediate real world ...
... have developed a novel, three-dimensional model that allows ... of metastatic melanoma cells induces normal skin cells ... migrate and spread throughout the body. , ... and colleagues at Children's Memorial Research Center, consists ...
Cached Biology News:Blocking the nerve receptor EP1 in mouse models reduces brain damage caused by stroke 2Blocking the nerve receptor EP1 in mouse models reduces brain damage caused by stroke 3Membrane research opens window to benefits for plants, humans 2Membrane research opens window to benefits for plants, humans 3Model identifies genes that induce normal skin cells to become abnormal 2
Vertical Rack (five box vapor phase rack), includes 2.0" (5.1cm) boxes...
... The 1-D PAGE ... Kit for Targeted Protein ... SDS PolyAcrylamide Gel Electrophoresis ... chemistry, and cleavable-linker technology ...
Conjugate Quality Control Evaluation Specificity: Conjugate Quality Control Evaluation ...
Qa-1 (L-12)...
Biology Products: